Yirui Pharma's First-in-Class Kv1.3 Inhibitor YR-001 Receives FDA IND Approval, Marking China's First-In-Class Entry into Global Autoimmune Drug Race

VCBeat New Medicine learned at the earliest opportunity,Hangzhou Yirui Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Yirui Pharma”) has officially received approval from the U.S. FDA to conduct clinical trials for its innovative drug YR-001 (NCT05718921).YR-001 is a potential first-in-class novel drug independently developed by Yirui Pharma for the treatment of autoimmune skin diseases. As a highly selective small-molecule inhibitor of the potassium ion channel Kv1.3, this product has demonstrated efficacy in preclinical models of several autoimmune diseases.

Kv1.3 is one of the internationally prominent innovative therapeutic targets. In June 2022, pharmaceutical giant Eli Lilly and Company acquired global clinical development and commercialization rights for DES-7114, a Kv1.3 inhibitor developed by D. E. Shaw Research (DESRES), for a total consideration of $535 million, including an upfront payment of $60 million. According to Yirui Pharma, the company holds independent global intellectual property rights for YR-001. As the first product in China targeting this same molecule, YR-001’s entry into clinical trials shortly after DES-7114 represents a significant milestone.

Yirui Pharma, established in 2018, is a biotech company dedicated to the research and development of innovative small-molecule targeted therapies. The company is committed to driving source innovation through strategic R&D approaches that emphasize scientifically grounded project selection, cost efficiency, high operational efficiency, and effective risk control. With in-house R&D as its core focus, Yirui Pharma addresses therapeutic areas including autoimmune diseases, diabetic complications, and chronic inflammatory conditions. It has implemented differentiated strategies across drug targets, indication selection, routes of administration, and target patient populations, striving to provide novel first-line treatments for the unmet clinical needs of hundreds of millions of patients worldwide. The company’s Series A financing round secured tens of millions of RMB in investment from renowned institutions such as Tigermed and Tianfeng Capital.

Over the past five years, Yirui Pharma has been dedicated to innovative R&D with minimal public presence in the industry. It was only after its investigational new drug (IND) application for a candidate in its development pipeline received approval from the U.S. Food and Drug Administration (FDA) that the company officially disclosed its R&D progress. Although not widely recognized within the industry, Yirui Pharma has steadily built robust R&D capabilities and established a product pipeline with differentiated competitive advantages, making it deserving of greater attention and recognition among industry stakeholders.

Yirui Pharma’s core R&D team comprises former executives from a German new drug development company and PhD holders who returned to China after studying in Germany. Dr. Wang Xiaolu, the company’s founder, Chairman, and Chief Scientific Officer, worked for 16 consecutive years at a renowned European innovative drug R&D enterprise, where he served as Senior Vice President. He participated in leading nearly 100 innovative drug projects and personally oversaw the R&D of more than 20 innovative drugs, accumulating extensive experience in early-stage project initiation and advancement, preclinical and early-phase clinical studies, and cross-border comprehensive management of innovative drug projects.

Currently, the company’s medicinal chemistry, pharmacology, and clinical teams are led by overseas-returnee PhDs and senior scientists with many years of experience in innovative drug R&D. Notably, the Chief Medical Officer has accumulated over 12 years of work experience at several renowned German pharmaceutical companies, gaining extensive expertise in clinical research. Having previously served as Clinical Project Director and Chief Clinical Strategy Officer, this individual has spearheaded preclinical studies and international multi-center clinical trials for multiple innovative drugs, and contributed to the successful regulatory approval and market launch of four innovative drugs in Europe and the United States.

In addition to focusing on new drug development, Yirui Pharma places equal emphasis on corporate operations. The company’s General Manager brings nearly 30 years of pharmaceutical marketing and management experience from multinational pharmaceutical companies and leading domestic healthcare enterprises. With in-depth knowledge of the biopharmaceutical landscape in China, he has helped the company achieve robust growth by effectively integrating localization with internationalization. Furthermore, Yirui Pharma has established a European subsidiary in Germany, led by Dr. D. Wulff, a seasoned business executive and scientist, to strengthen its international collaboration capabilities and accelerate the global commercialization of its pipeline in line with strategic objectives.

Currently, the development of new drugs for the pediatric population urgently needs to be expanded, as this group not only has substantial clinical needs but also imposes extremely high requirements for drug safety. Yirui Pharma’s YR-001 ensures its safety through multiple aspects, including target mechanism, drug molecule, and administration route. Preclinical data demonstrate that YR-001 offers significantly improved safety and efficacy compared with other targeted therapies. Therefore, it holds promise for use in infants and young children, addressing the current lack of available treatments for this population.

Furthermore, Yirui Pharma has strategically positioned itself with innovative targets in several chronic disease areas characterized by significant unmet clinical needs, high incidence rates, and large market potential, such as diabetic retinopathy, chronic kidney disease, and ulcerative colitis (IBD). Currently, Yirui Pharma is accelerating its R&D efforts to ensure patients benefit from these therapies as soon as possible. In addition to the YR-001 program, Yirui Pharma plans to submit Investigational New Drug (IND) applications for two additional innovative drug candidates this year.

Regarding Yirui Pharma’s milestone progress,Dr. Wang Xiaolu, Founder of Yirui Pharma, stated“This marks the company’s first Investigational New Drug (IND) application approved by the U.S. FDA, covering two indications. We are now prepared to initiate Phase I clinical trials in the United States and plan to conduct global multi-center collaborative clinical studies in the future. This milestone is highly significant, demonstrating Yirui Pharma’s internationalization capabilities and aligning with our original intention and goal of developing global products. Currently, multiple projects under development at the company are at the international forefront; the selected targets have undergone robust validation, are essentially exclusive in China, and are being developed concurrently by only a very small number of companies worldwide. Moving forward, we will submit IND applications for more innovative drug candidates, striving to develop innovative medicines with genuine clinical value to benefit patients globally.”

Wang Ruwei, a member of the National Pharmacopoeia Committee and partner at Hangzhou Tailong Investment, stated“The core technical team at Yirui Pharma boasts extensive international and industrialization experience, along with advanced concepts in top-level product design and scientific management. Meanwhile, Yirui Pharma demonstrates strong business development (BD) capabilities, ensuring seamless market integration and achieving breakthroughs in international cooperation, which makes it highly promising. The company is currently accelerating the regulatory filing of its innovative drugs, with two additional new drug candidates expected to submit Investigational New Drug (IND) applications this year. We look forward to the company developing innovative therapies with greater clinical value to benefit humanity and realize its vision.”

Guan Jifeng, Founding Partner of Tianfeng Capital, stated“The Yirui Pharma team possesses a global perspective and advanced project management capabilities, proactively mitigating development risks associated with original targets, securing core value across the innovative drug R&D industry chain, and optimizing the allocation of global resources. More importantly, the team has deep expertise in the top-level strategic design approaches of major global pharmaceutical companies, constructing its R&D pipeline with a market- and patient-centric focus to benefit more patients while enhancing long-term medication safety. We look forward to Yirui Pharma, as a pioneer among China’s new generation of biotech companies, bringing more high-quality novel therapies to patients worldwide.”

While most attention is drawn to the star enterprises in the industry, low-profile companies naturally receive less spotlight. Yet, beneath their understated exterior, they are continuously developing drugs with greater clinical value and innovation. Innovative drug R&D companies like Yirui Pharma hold promising potential for future breakthroughs.